Review: Multiple system atrophy: emerging targets for interventional therapies

Multiple system atrophy (MSA) is a fatal orphan neurodegenerative disorder that manifests with rapidly progressive autonomic and motor dysfunction. The disease is characterized by the accumulation of α‐synuclein fibrils in oligodendrocytes that form glial cytoplasmic inclusions, a neuropathological hallmark and central player in the pathogenesis of MSA. Here, we summarize the current knowledge on the etiopathogenesis and neuropathology of MSA. We discuss the role of α‐synuclein pathology, microglial activation, oligodendroglial dysfunction and putative cell death mechanisms as candidate therapeutic targets in MSA.

• Publication year

  2016

• Venue

  Neuropathology and Applied Neurobiology

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/nan.12304PMID 26785838PMCID 4788141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutant COQ2 in Multiple-System Atrophy

  2017cited by this paper
• Genome-wide estimate of the heritability of Multiple System Atrophy.

  2016cited by this paper
• Review: Multiple system atrophy: emerging targets for interventional therapies

  2016cited by this paper
• When DLB, PD, and PSP masquerade as MSA

  2015cited by this paper
• Microglial cell dysregulation in brain aging and neurodegeneration

  2015cited by this paper
• Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications

  2015cited by this paper
• Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity

  2015cited by this paper
• Filamentous aggregations of phosphorylated α-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy

  2015cited by this paper
• Distinctive distribution of phospho‐alpha‐synuclein in dermal nerves in multiple system atrophy

  2015cited by this paper
• Progressive retinal structure abnormalities in multiple system atrophy

  2015cited by this paper
• Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

  2015cited by this paper
• Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy

  2015cited by this paper
• Expanding the spectrum of neuronal pathology in multiple system atrophy.

  2015cited by this paper
• Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism

  2015cited by this paper
• Alpha-Synuclein Expression in the Oligodendrocyte Lineage: an In Vitro and In Vivo Study Using Rodent and Human Models

  2015cited by this paper
• Altered Expression of miR-202 in Cerebellum of Multiple-System Atrophy

  2015cited by this paper
• Variants associated with Gaucher disease in multiple system atrophy

  2015cited by this paper
• The Global Cognition, Frontal Lobe Dysfunction and Behavior Changes in Chinese Patients with Multiple System Atrophy

  2015cited by this paper
• Multiple-system atrophy.

  2015cited by this paper
• Minimal change multiple system atrophy: An aggressive variant?

  2015cited by this paper
• Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy.

  2015cited by this paper
• Natural History of Multiple System Atrophy in North America: A Prospective Cohort Study

  2015cited by this paper
• Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.

  2015cited by this paper
• Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy - A stereological study.

  2015cited by this paper
• Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.

  2015cited by this paper
• SNP rs11931074 of the SNCA gene may not be associated with multiple system atrophy in Chinese population

  2015cited by this paper
• α-Synuclein strains cause distinct synucleinopathies after local and systemic administration

  2015cited by this paper
• Mutant COQ2 in multiple-system atrophy.

  2014cited by this paper
• Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy

  2014cited by this paper
• Multiple System Atrophy: Genetic or Epigenetic?

  2014cited by this paper
• Towards translational therapies for multiple system atrophy

  2014cited by this paper
• Widespread microRNA dysregulation in multiple system atrophy – disease‐related alteration in miR‐96

  2014cited by this paper
• Exploring Myelin Dysfunction in Multiple System Atrophy

  2014cited by this paper
• XIAP immunoreactivity in glial and neuronal cytoplasmic inclusions in multiple system atrophy.

  2014cited by this paper
• Analysis of COQ2 gene in multiple system atrophy

  2014cited by this paper
• Alpha-synuclein mRNA expression in oligodendrocytes in MSA

  2014cited by this paper
• Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy

  2014cited by this paper
• Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy

  2014cited by this paper
• Neuropathology of multiple system atrophy: New thoughts about pathogenesis

  2014cited by this paper
• Alpha‐synuclein transfers from neurons to oligodendrocytes

  2014cited by this paper
• Bladder dysfunction in a transgenic mouse model of multiple system atrophy

  2013cited by this paper
• A randomized clinical trial of lithium in multiple system atrophy

  2013cited by this paper
• Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence

  2013cited by this paper
• Mutations in COQ2 in familial and sporadic multiple-system atrophy.

  2013cited by this paper
• Identification and Quantification of Oligodendrocyte Precursor Cells in Multiple System Atrophy, Progressive Supranuclear Palsy and Parkinson's Disease

  2013cited by this paper
• Alteration of autophagosomal proteins in the brain of multiple system atrophy.

  2013cited by this paper
• A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type

  2013cited by this paper
• Transmission of multiple system atrophy prions to transgenic mice

  2013cited by this paper
• Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia

  2013cited by this paper
• Premotor signs and symptoms of multiple system atrophy.

  2012cited by this paper
• Analysis of colonic alpha-synuclein pathology in multiple system atrophy.

  2012cited by this paper
• The Role of Glia in Alpha-Synucleinopathies

  2012cited by this paper
• Involvement of Macroautophagy in Multiple System Atrophy and Protein Aggregate Formation in Oligodendrocytes

  2012cited by this paper
• Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model

  2012cited by this paper
• The neuropathology, pathophysiology and genetics of multiple system atrophy

  2012cited by this paper
• A randomized trial of mesenchymal stem cells in multiple system atrophy

  2012cited by this paper
• Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice

  2012cited by this paper
• Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

  2012cited by this paper
• Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy

  2012cited by this paper
• Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts

  2011cited by this paper
• Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection

  2011cited by this paper
• Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons.

  2011cited by this paper
• Targeted overexpression of human α-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure

  2010cited by this paper
• Neural control of the bladder

  2010cited by this paper
• Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors

  2010cited by this paper
• Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)

  2010cited by this paper
• Differential involvement of the periaqueductal gray in multiple system atrophy.

  2010cited by this paper
• SNCA variants and multiple system atrophy

  2010cited by this paper
• Reply to: SNCA variants are associated with increased risk of multiple system atrophy

  2010cited by this paper
• Genetic Variants of the α-Synuclein Gene SNCA Are Associated with Multiple System Atrophy

  2009cited by this paper
• SNCA variants are associated with increased risk for multiple system atrophy

  2009cited by this paper
• Multiple system atrophy: an update.

  2009cited by this paper
• Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study

  2008cited by this paper
• Multiple system atrophy: A primary oligodendrogliopathy

  2008cited by this paper
• Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.

  2008cited by this paper
• Rifampicin reduces &agr;-synuclein in a transgenic mouse model of multiple system atrophy

  2008cited by this paper
• Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy

  2008cited by this paper
• Glial cytoplasmic inclusions and tissue injury in multiple system atrophy: A quantitative study in white matter (olivopontocerebellar system) and gray matter (nigrostriatal system)

  2008cited by this paper
• Second consensus statement on the diagnosis of multiple system atrophy

  2008cited by this paper
• Microglial activation mediates neurodegeneration related to oligodendroglial α‐synucleinopathy: Implications for multiple system atrophy

  2007cited by this paper
• p25α Relocalizes in Oligodendroglia from Myelin to Cytoplasmic Inclusions in Multiple System Atrophy

  2007cited by this paper
• p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy.

  2007cited by this paper
• Multiple system atrophy: α‐synuclein and neuronal degeneration

  2007cited by this paper
• Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study

  2007cited by this paper
• Dynamics of α‐synuclein aggregation and inhibition of pore‐like oligomer development by β‐synuclein

  2007cited by this paper
• Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.

  2007cited by this paper
• Involvement of vagal autonomic nuclei in multiple system atrophy and Lewy body disease

  2006cited by this paper
• Absence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia

  2005cited by this paper
• Case–control study of multiple system atrophy

  2005cited by this paper
• When is Onuf’s nucleus involved in multiple system atrophy? A sphincter electromyography study

  2005cited by this paper
• Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia.

  2005cited by this paper
• Neurological and Neurodegenerative Alterations in a Transgenic Mouse Model Expressing Human α-Synuclein under Oligodendrocyte Promoter: Implications for Multiple System Atrophy

  2005cited by this paper
• Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.

  2005cited by this paper
• Animal models of multiple system atrophy

  2005cited by this paper
• Epidemiological evidence on multiple system atrophy

  2005cited by this paper
• Microglial Activation Parallels System Degeneration in Multiple System Atrophy

  2004cited by this paper
• The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations.

  2004cited by this paper
• Involvement of medullary serotonergic groups in multiple system atrophy

  2004cited by this paper
• Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy

  2004cited by this paper

• Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes

  2026cites this paper
• Nanocarrier Advancements Revolutionizing Treatment for Neurodegenerative Diseases

  2025cites this paper
• Autonomic dysfunction in multiple system atrophy: from pathophysiology to clinical manifestations

  2025cites this paper
• [Cognitive impairment in multiple system atrophy - exclusion criteria or an integral part of the clinical picture?]

  2024cites this paper
• Exploring Machine Learning Approaches for Transcriptome-Based Diagnosis and Subgrouping of Multiple System Atrophy

  2024cites this paper
• Diagnostic value and correlation analysis of serum cytokine levels in patients with multiple system atrophy

  2024cites this paper
• Neurodegeneration cell per cell.

  2023cites this paper
• Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments

  2023cites this paper
• Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects

  2022cites this paper
• Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?

  2022cites this paper
• Identification of cyclin D1 as a major modulator of 3-nitropropionic acid-induced striatal neurodegeneration.

  2021cites this paper
• The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders

  2021cites this paper
• Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson’s disease

  2021cites this paper
• Reliability and validity of Japanese version of Unified Multiple System Atrophy Rating Scale

  2021cites this paper
• In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons

  2020cites this paper
• Multiple System Atrophy (MSA) and smoking: a meta-analysis and mechanistic insights

  2020cites this paper
• MSA: From basic mechanisms to experimental therapeutics.

  2020cites this paper
• Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies

  2020influential citation
• High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α-synucleinopathy

  2020cites this paper
• The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question—are polyphenols a viable therapeutic option against proteinopathies?

  2020cites this paper
• Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease

  2020cites this paper
• Assessment of the Retina of Plp-α-Syn Mice as a Model for Studying Synuclein-Dependent Diseases

  2020cites this paper
• Signs of early cellular dysfunction in multiple system atrophy

  2020cites this paper
• The molecular tweezer CLR 01 reduces aggregated , pathologic , and seeding-competent α-synuclein in experimental multiple system atrophy

  2019cites this paper
• Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy.

  2019cites this paper
• Similarities and differences in cerebellar grey matter volume and disrupted functional connectivity in idiopathic Parkinson's disease and multiple system atrophy

  2019influential citation
• Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.

  2019cites this paper
• Promises and Challenges of MSC-Based Therapies: Parkinson Disease and Parkinsonism

  2019cites this paper
• FTY720-mitoxy reduces toxicity associated with α-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures.

  2019cites this paper
• The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.

  2019cites this paper
• Cross-examining candidate genes implicated in multiple system atrophy

  2019cites this paper
• Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (α-Syn) Pathology in Synthetic α-Syn Fibril-Induced Mouse Models of Synucleinopathy.

  2019cites this paper
• FTY720-mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in multiple system atrophy mice.

  2019cites this paper
• Nanobiotechnology in Neurodegenerative Diseases

  2019cites this paper
• The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint

  2018cites this paper
• AMBRA1, a novel α‐synuclein‐binding protein, is implicated in the pathogenesis of multiple system atrophy

  2018cites this paper
• [Current therapy studies in atypical Parkinson syndromes].

  2018cites this paper
• abnormal functional connectivity of the amygdala is associated with depressive symptoms in patients with multiple system atrophy

  2018cites this paper
• Abnormal functional connectivity of the amygdala is associated with depressive symptoms in patients with multiple system atrophy

  2018cites this paper
• Extensive Delayed Brain Atrophy after Resuscitation in a Patient with Multiple System Atrophy

  2018cites this paper
• The neuropathology of multiple system atrophy and its therapeutic implications.

  2017cites this paper
• Biomarkers in Parkinson's disease and related disorders. Diagnostic value of biochemical markers and their relation to disease progression

  2017cites this paper
• FTY720 (Fingolimod) reverses &agr;‐synuclein‐induced downregulation of brain‐derived neurotrophic factor mRNA in OLN‐93 oligodendroglial cells

  2017cites this paper
• Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases

  2017cites this paper
• Multiple system atrophy: insights into a rare and debilitating movement disorder

  2017cites this paper
• Multiple system atrophy: experimental models and reality

  2017cites this paper
• Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy

  2017cites this paper
• Multiple system atrophy: pathogenic mechanisms and biomarkers

  2016cites this paper
• Zanik wieloukładowy — algorytm diagnostyczny i możliwości leczenia

  2016cites this paper
• Review: Multiple system atrophy: emerging targets for interventional therapies

  2016cites this paper
• Synucleinopathies: past, present and future

  2016cites this paper
• Expanding concept of clinical conditions and symptoms in multiple system atrophy.

  2016cites this paper
• Overlaps between multiple system atrophy and multiple sclerosis: A novel perspective

  2016cites this paper
• MicroRNA expression profiles of multiple system atrophy from formalin-fixed paraffin-embedded samples.

  2016cites this paper
• Recent advances in multiple system atrophy

  2016cites this paper